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Abstract: This study was performed to evaluate the ability of N-(2-hydroxypropyl)-3-tri 
methylammonium chitosan chloride (HTCC), the cationically modified chitosan, to form 
biologically inactive complexes with unfractionated heparin and thereby blocking its 
anticoagulant activity. Experiments were carried out in rats in vivo and in vitro using the 
activated partial thromboplastin time (APTT) and prothrombin time (PT) tests for 
evaluation of heparin anticoagulant activity. For the first time we have found that HTCC 
effectively neutralizes anticoagulant action of heparin in rat blood in vitro as well as in rats 
in vivo. The effect of HTCC on suppression of heparin activity is dose-dependent and its 
efficacy can be comparable to that of protamine-the only agent used in clinic for heparin 
neutralization. HTCC administered i.v. alone had no direct effect on any of the coagulation 
tests used. The potential adverse effects of HTCC were further explored using rat experimental 
model of acute toxicity. When administered i.p. at high doses (250 and 500 mg/kg body 
weight), HTCC induced some significant dose-dependent structural abnormalities in the 
liver. However, when HTCC was administered at low doses, comparable to those used for 
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neutralization of anticoagulant effect of heparin, no histopathological abnormalities in liver 
were observed. 




Heparin, usually used in cardiovascular surgery to prevent thromboembolism, often leads to a high 
incidence of bleeding complications. To reverse its anticoagulant action, protamine sulfate is routinely 
used. Protamine consists of a group of heterogeneous cationic peptides obtained from fish and its 
antiheparin activity results from the attractive electrostatic interaction with anionic heparin [1]. It is a 
relatively safe drug; however, its administration is occasionally associated with severe, life-threatening 
reactions, including significant systemic hypotension, severe pulmonary hypertension, anaphylactic 
shock, fatal cardiac arrest as well as thrombocytopenia [2]. Although adverse events after protamine 
administration might be associated with significant morbidity and mortality, there is a lack of clinically 
reliable alternative substance for heparin neutralization. 
In an attempt to address this clinical problem, we tested a modified chitosan—a polymer derived 
from chitin through partial deacetylation—as a potentially effective heparin antagonist. Chitosan, as a 
cationic polysaccharide, can interact with negatively charged (macro)molecules. This feature was 
essential for our concept that chitosan can interact with heparin. Chitosan is one of the most promising 
polymers in the biomedical field because of its biocompatibility and biodegradability [3,4]. In recent 
years, chemically modified chitosans, developed in order to improve the properties of the native 
chitosan for oral drug delivery, have gained increasing attention [5–7]. Moreover, other beneficial 
properties such as antitumor, hypocholesterolemic, weight lowering, antioxidant, neuroprotective, and 
antimicrobial presented it to nutritional health supplements [7–9]. 
However, the main limitations on use of chitosan in several applications are its high viscosity and 
low solubility at neutral pH. Thus, N-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride (HTCC), 
a bioactive cationically modified chitosan has been obtained by the chemical substitution of chitosan 
with glycidyltrimethylammonium chloride (GTMAC) containing cationic ammonium groups [10]. The 
main rationale for carrying out chemical modification of the chitosan molecule was to obtain a 
compound with good solubility at physiological pH—ideally at pH = 7.4 which is the value typical for 
blood, allowing to perform animal study with the use of i.p. and/or i.v. routes of administration. 
Cationically modified (quaternized) chitosan is a beige-colored, solid-stated, stable at room temperature 
substance that can be powdered. HTCC shows good solubility at physiological pH and displays a high 
efficiency of heparin binding. Finally, it was proved that in model buffers at neutral pH HTCC forms 
complexes with heparin molecules [10,11]. Therefore, the aim of our study was to test the ability of 
HTCC to neutralize anticoagulant activity of heparin in rat blood in vitro and in vivo.  
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2. Materials and Methods 
2.1. Materials 
Heparin sodium injection (5000 USP units/mL) was purchased from Polfa (Warsaw, Poland). 
Protamine sulfate salt was purchased from Sigma-Aldrich (St. Louis, MO, USA). HTCC was prepared 
from native chitosan (Sigma-Aldrich, St. Louis, MO, USA) according to the procedure described 
previously [10]. The solutions of heparin, protamine and HTCC were prepared in 0.9% NaCl. 
2.2. Animals 
The experiments were carried out using Wistar male rats. The animals were kept in plastic  
cages in a room temperature with a 12:12 light:dark cycle. They were fed with a standard chow diet 
and had free access to water. All experiments were conducted according to the Guidelines for  
Animal Experiments, Jagiellonian University, Poland. The study was approved by the First Local 
Ethical Committee on Animal Testing at the Jagiellonian University in Krakow, Poland (decision 
74/2010 valid from 7 July 2010 to July 2013; decision Zi/497/2009 valid from 9 February 2009 to  
9 February 2014). 
2.3. In Vitro Experiments  
The experiments were carried out on blood of rats weighing 430–495 g. Animals were anesthetized 
with 30 mg/kg sodium pentobarbital and carotid artery was cannulated. Arterial blood was collected 
into plastic tubes containing 3.18% sodium citrate (9:1, v:v blood to anticoagulant). Each sample, 
containing 1.5 mL of blood, was treated for 5 min with heparin alone at concentrations from 0.5 to 3.0 IU 
per 1.0 mL of blood. Blood was also treated with heparin in combination with HTCC or protamine at 
the concentration adjusted to neutralize heparin activity, i.e., 1.4 mg of HTCC and 1.2 mg of protamine 
for each 120 IU (about 1 mg) of heparin, the proportions determined previously using model buffers [10]. 
Then, the samples were mixed gently. In control samples, 0.9% NaCl was added to blood. Blood was 
also treated with HTCC or protamine alone at concentrations corresponding to those used in 
experiments with heparin. For measurements of blood clotting parameters, blood plasma was separated 
by centrifugation at 1200× g for 5 min at 4 °C, frozen and stored at −80 °C until coagulation assays 
were performed. Each experiment was performed three times. 
2.4. In Vivo Experiments 
In vivo experiments were performed on animals weighing 310–375 g. Animals were anesthetized 
with 30 mg/kg sodium pentobarbital and femoral vein and carotid artery were cannulated. The animals 
were divided into six experimental groups.  
Group 1: control rats (n = 3) that received physiological saline i.v. (500 μL of 0.9% NaCl).  
Group 2: rats (n = 3) pretreated with heparin i.v. (dissolved in saline, 1 IU/g body weight).  
Group 3: rats (n = 6) pretreated i.v. with heparin (1 IU/g body weight) and next with HTCC i.v. at a 
dose of 1.4 mg per each 120 IU of given heparin. 
Group 4: rats (n = 6) were given i.v. injection of HTCC at a dose adjusted to neutralize heparin.  
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Group 5: rats (n = 3) pretreated i.v. with heparin (1 IU/g body weight) and then injected with 
protamine i.v. at a dose of 1.2 mg per each 120 IU of pre-injected heparin.  
Group 6: rats (n = 3) injected with protamine i.v. at a dose adjusted to neutralize heparin activity. 
The dose of heparin administered to rats was 1 IU/g body weight. The dose of protamine was  
based on the in vitro established neutralization dose, i.e., 1.2 mg:120 IU (protamine:heparin).  
The dose of HTCC administered to achieve a complete heparin neutralization was determined earlier 
in model buffers (PBS, 0.9% NaCl) and was based on the proportion 1.4 mg:120 IU (HTCC:heparin), 
thus the total HTCC dose administered i.v. was 11.6 mg/kg. These compounds were administered 
intravenously into femoral vein and blood samples were collected from carotid artery into plastic tubes 
containing 3.18% sodium citrate after 30 and 60 min. Before each tested substance administration 
control samples were collected. Blood samples were also collected 5 min after heparin administration. 
For the measurements of hemostatic parameters blood plasma was obtained in the same manner as in 
the in vitro tests. 
2.5. Hemostatic Parameters 
The coagulation screening tests, i.e., activated partial thromboplastin time (APTT), prothrombin 
time (PT), and fibrinogen (Fb) concentration were performed with commercially available coagulometer 
(Hemostasis Analyzer, Start-4
®
, Diagnostica Stago, Roche Diagnostics) by modifications of the 
conventional clinical procedures [12,13]. APTT and PT values are represented in seconds and Fb 
concentration is expressed as mg/dL. 
2.6. Pathomorphological Examination of the Liver 
The experiments were carried out on rats weighing 200–265 g. Rats were randomly divided into 
four groups (control group and three groups injected i.p. with various doses of HTCC). Each group 
consisted of 3 animals. The doses were 25, 200 and 500 mg/kg body weight i.p. for HTCC dissolved in 
physiological saline; 500 μL of 0.9% saline was injected as a control. The survival time of each animal 
was recorded for up to 24 h. Then animals were anesthetized with 30 mg/kg sodium pentobarbital and 
sacrificed by cervical dislocation. Livers of rats were fixed by the pulsating-perfusion method. At first, 
blood was washed out with saline, then 4% buffered formalin was injected. A portion of liver tissue 
was taken for histological evaluation. Liver tissue samples were embedded in paraffin blocks after 
routine tissue preparation procedures (dehydration in alcohol, clearing in xylitol), cut into 5 μm thick 
sections with a microtome blade. Sections from the liver of each animal involved in the study were 
stained with hematoxylin and eosin for general histological investigations (for evaluation of  
necro-inflammatory grading), and with oil red O for the evaluation of fatty droplets.  
2.7. Statistical Analysis 
Data were expressed as the mean ± SEM. Statistical significance and differences among groups 
were determined by ANOVA one-way test. p < 0.05 values were considered statistically significant.  
  




3.1. Effect of HTCC on Hemostatic Parameters of Rat Blood in Vitro 
Mean APTT value of rat blood in control experiments was 17.2 s ± 1.03 s (n = 3). The 
administration of heparin resulted in an increase of APTT level, observed for every half unit of heparin 
added (Figure 1). On the basis of these results, we chose a dose of 3 IU of heparin/mL of blood to 
study the effect of HTCC on hemostatic parameters. The selected dose of heparin was found to be 
suitable for stable and reproducible APTT elevation. HTCC caused a dose-dependent decrease in 
APTT level of heparinized rat blood (Figure 2). The most effective dose of chitosan was 1.4 mg  
per 120 IU of heparin, as determined earlier for model buffers [10]. The effect of HTCC administration 
on APTT level reduction was comparable to that produced with protamine (Figure 3a). Neither 
modified chitosan nor protamine given alone influenced the APTT level, as compared to control 
(Figure 3a). HTCC decreased PT in heparinized blood and this effect was similar to that produced by 
protamine (Figure 3b). In contrast to protamine, HTCC alone did not influence PT level (Figure 3b). 
As shown on Figure 3c, the addition of HTCC to heparinized blood resulted in a slight increase of 
fibrinogen concentration, however, this effect was not statistically significant. 
Figure 1. HTCC and protamine reverse the anticoagulant effect of heparin as measured by 
APTT in rat blood in vitro (n = 3 experiments for each point), results are expresses as 
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Figure 2. Effect of incremental concentration of HTCC on reversal of heparin activity 
(heparin used at a dose of 3 IU per 1 mL of blood sample) in rat blood in vitro. APTT 
values are expressed as mean ± SEM and 6 samples were used for each plotted data point.  
 
Figure 3. The influence of heparin, HTCC, and protamine on APTT (a); PT (b) and 
fibrinogen (c) levels in rat blood in vitro (results are expressed as mean ± SEM from n = 6 
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Figure 3. Cont. 
 
(c) 
3.2. Hemostatic Effects of HTCC in Rats in Vivo 
There was no significant difference in APTT level in the control group during the evaluation period 
(0, 30 and 60 min) (Figure 4). After i.v. administration of heparin APTT was significantly increased, 
reaching maximal level (84.7 s ± 13.53 s) after 30 min (Figure 4). In rats pretreated with heparin, after 
HTCC administration the most significant drop of APTT and PT level was achieved just after 30 min 
and was still observed at 60 min after injection (Figure 4). Compared to the control group, HTCC as 
well as protamine injected alone, did not influence APTT or PT level (Figure 5a,b). As shown on 
Figure 5c, only protamine induced slight increase in fibrinogen level compared to the control group, 
but this effect was not statistically significant. 
Figure 4. Comparison of the effects of HTCC and protamine on APTT in blood  
in vivo (the plotted data are expressed as mean ± SEM from n = 3–6 experiments,  
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Figure 5. Effect of HTCC and protamine on coagulation tests: APTT (a); PT (b); 
fibrinogen concentration (c) in blood in vivo at 60 min after HTCC administration. The 
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Figure 6. Changes of histopathological image of rat liver after i.p. administration of HTCC 
(hematoxylin and eosin staining). (A,B) Photomicrographs of control rat liver. The lobular 
structure of the liver is preserved. Portal tracts of normal size, without increase of collagen 
fibers and without inflammatory infiltrates. Proper bile ducts are present in all portal tracts. 
The structure of the cytoplasm is preserved in all hepatocytes. No signs of fatty change 
(original magnification A × 20, B × 40); (C,D) Photomicrographs of rat liver after i.p. 
administration of 25 mg/kg of HTCC. The lobular structure of the liver is preserved. Portal 
tracts of normal size, without increase of collagen fibers and without inflammatory 
infiltrates. Proper bile ducts are present in all portal tracts. Microvesicular fatty change 
concentrated around central veins (zone 3 of Rappaport) is seen in about 40% of 
hepatocytes (original magnification C × 20, D × 40); (E,F) Photomicrographs of rat liver 
after i.p. administration of 200 mg/kg of HTCC. The lobular structure of the liver is 
preserved. The signs of congestion are visible. Portal tracts of normal size, without 
increase of collagen fibers and without inflammatory infiltrates. Proper bile ducts are 
present in all portal tracts. The structure of the cytoplasm is damaged in majority of 
hepatocytes. Isolated necrosis of hepatocytes mainly in the perivenular zone and sparse 
binucleated hepatocytes are present. No signs of fatty change (original magnification  
E × 20, F × 40); (G,H) Photomicrographs of rat liver after i.p. administration of  
500 mg/kg of HTCC. The lobular structure of the liver is preserved. The signs of severe 
congestion are visible. Portal tracts of normal size, without increase of collagen fibers and 
without inflammatory infiltrates. Proper bile ducts are present in all portal tracts. 
Microvesicular fatty change concentrated around central veins (zone 3 of Rappaport) is 
seen in about 80%–90% of hepatocytes (original magnification G × 20, H × 40). 
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Figure 6. Cont. 
 
3.3. Histopathological Findings 
All rats survived i.p. administration of HTCC. The histopathological assessment of liver was 
performed for all experimental groups. Rats in the saline control group showed normal, well defined 
liver histological structures without any signs of vascular or inflammatory changes (Figure 6A,B). All 
tested doses of HTCC did not influence the lobular structure of the liver and also portal tracts were 
intact without increase of collagen fibers and without inflammatory infiltrates. In histopathological 
evaluation of the liver tissue samples, there were no significant changes between control group and 
group administered with 25 mg/kg dose of HTCC. However, some fatty changes were observed after 
HTCC administration (Figure 6C,D). The 200 and 500 mg/kg doses of HTCC induced liver damage 
(Figure 6E–H). We observed some dose-dependent structural changes, like microvesicular fatty 
changes concentrated around central veins (zone 3 of Rappaport) in 40% of hepatocytes in group 
treated with 25 mg/kg of HTCC to 80%–90% of hepatocytes in the group treated with 500 mg/kg. 
However, in our study total dose of HTCC used i.v. in rats for reversing heparin activity  
was 11.6 mg/kg and this dose appeared to be non-toxic. 
4. Discussion 
In this study, we have investigated antiheparin potential of HTCC by measuring its effects on blood 
hemostatic parameters in rats. It was shown earlier that HTCC had the ability of forming a complex 
with heparin [10]. However, this was only demonstrated in model buffers. Here, for the first time we 
have found that HTCC may neutralize anticoagulant activity of heparin also in blood, as revealed by 
significant APTT reduction in rats in vitro. Moreover, we also tested in vivo anticoagulant activity of 
HTCC. We have provided clear evidence that in rats pretreated with heparin, intravenous administration 
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of HTCC significantly lowers APTT level in a dose-dependent manner. In our experiments in rats the 
administration of HTCC at a dose of 1.4 mg per 120 IU of heparin (about 1 mg of heparin) effectively 
leads to the normalization of APTT. The pharmacological antiheparin activity of the studied polymer 
is comparable to that of protamine—the only agent used so far in clinic for heparin neutralization.  
To our knowledge, there are no reports, describing the effect of chitosan on coagulation parameters 
of heparinized blood in vivo and a number of significant restrictions to study this compound in vivo 
result from its unfavorable physicochemical properties. It is well known, that high molecular weight 
and high viscosity of chitosan may limit its use in vivo [14]. Non-modified chitosan is soluble at acidic 
pH that makes it difficult to use it intravenously [15]. Therefore, several chemical methods have been 
developed to prepare safe and biologically active low molecular weight compounds. However, they are 
expensive since their synthesis is complicated and laborious [16–18]. That is why there is only a little 
data, regarding the effect of chitosan and its derivatives having different physicochemical properties on 
the blood coagulation in vivo. HTCC tested in this study has a good solubility at neutral pH (previously 
shown in model buffers) and thus it is possible to perform in vivo experiments involving its parenteral 
administration [10]. 
It is important to mention that chitosans with their diverse chemical structure show a variety of 
biological activities, and not all of these biological activities may be at the same time shown in all 
types of chitosans [4,19]. Chitosan has three types of reactive functional groups: an amino/acetamido 
group as well as primary and secondary hydroxyl groups. Many novel chitosan derivatives have been 
recently obtained by chemical modification of these groups [7]. However, the distribution of the acetyl 
groups along the chitosan molecules seems to be of crucial importance for its interaction with the 
biological systems [17]. In some cases the molecular weight plays a dominant role [19,20]. Regarding 
the effects of different chitosans on hemostasis, there are some reports of an in vitro and in vivo 
experiments and they are focused on their influence on platelet function, red blood cells aggregability, 
or blood coagulation time (BCT) [21–23]. It was shown that chitin and chitosan suspensions at 
concentrations up to 1 mg/mL reduced BCT significantly in a concentration-dependent manner and 
enhanced the release of some platelet factors (e.g., PDGF-AB, TGF-β1) [23]. On the other hand, it was 
found that chitosan is an effective inductor of platelet adhesion and aggregation and the mechanism of 
its action includes intracellular free Ca
2+
 mobilization and enhancing expression of platelet GPIIb/IIIa 
complex, increasing the expression of αIIbβ3 integrins and P-selectin [7,21,24,25]. These results 
indicate that hemostatic activity of chitosan may be independent of the classical coagulation cascade. 
However, it is also believed that coagulation of blood may be activated by chitosan and it appears to go 
via activation of platelets with the direct participation of plasma and extracellular matrix proteins [24].  
It was already revealed that upon exposure of whole blood to chitosan the thrombus is formed  
very rapidly [7,26].  
Zhang et al. measured in blood in vitro coagulative activity of chitosan hydrochloride with different 
degree of acetylation and molecular weight, using tube and capillary tube methods [7]. They found that 
the solution of chitosan hydrochloride with higher degree of acetylation (DA) and molecular weight 
(Mw) exhibited better hemostatic activity while for the powdered form of chitosan the effect of DA 
and Mw was only slight. Moreover, the comparative study carried out using solid chitosan and 
chitosan acetic acid physiological saline solution revealed disparate hemostatic mechanisms produced 
by different chitosans. The addition of chitosan acetic acid physiological saline solution to blood 
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resulted in the aggregation and deformation of erythrocyte membranes. However, solid-state chitosan 
with a high deacetylation degree bound more platelets and was more hemostatic [7]. The end-point of 
these cited studies was the analysis of platelet and/or erythrocyte aggregatory function, however, there 
is still no assured verdict of the mechanism by which these different chitosans act to stop bleeding. 
Some researchers were convinced that chitosan could induce clot formation in the absence of platelets, 
thus postulating the platelet-independent mechanism [27]. Earlier it has been found that coagulation 
factors could not be activated by chitosan and its derivatives [27,28]. It should also be recalled that the 
lack of direct relation of chitosan with the intrinsic or extrinsic pathways of coagulation was observed 
as often [7,27] as that chitosan film may activate the coagulation complementary systems [24].  
Our in vivo experiments in rats revealed that HTCC administered separately at doses adjusted for 
complete binding of heparin did not influence coagulation factors as evidenced by unchanged APTT, 
PT, and fibrinogen level. Thus, here we suggest that HTCC is a neutral and biocompatible polymer 
and it does not affect classical coagulation cascade. 
An organ damaged during in vivo experiments in rabbits revealed that chitosan could promote rapid 
blood clotting in lung, spleen and kidney injuries, and also reduces the amount of bleeding, exerting a 
substantial in vivo hemostatic effect [7]. However, all of these experiments were performed in the 
absence of exogenous heparin. Even in a therapeutically anticoagulated (heparinized) rabbit model, 
chitosan treatment could effectively bring bleeding time within the normal range [29]. Thus, the 
properties of chitosan to clot blood rapidly has gained its approval for use in internal bandages and 
other hemostatic agents. So far, only in its chemically purest form chitosan has an internal hemostatic 
dressing potential [7]. 
As revealed earlier in model buffers, HTCC is able to bind not only unfractionated heparin, but also 
low molecular weight heparins (LMWHs) [10]. This unexpected observation will be elucidated in vivo, 
since until now, there is not known antidote for LMWHs. It seems that cationic modification of 
chitosan may be responsible not only for a good solubility at neutral pH, but also for the increase of its 
chemical binding force both to heparin as well as to a variety of its derivatives [10].  
At the same time, however, it cannot be excluded that chitosan modification leads also to its 
increased binding to other blood components (e.g., blood proteins, erythrocytes, platelets). Unlike 
chains of most of polysaccharides, the chitosan macromolecules are positively charged and this property 
may be responsible for many biological activities related to binding to negatively charged surfaces. 
Indeed, it was already found that large amounts of fibrinogen and other plasma proteins may be bound 
to chitosan [24]. According to our experiments, the level of fibrinogen, as measured both in vivo and  
in vitro as well as with or without the pretreatment with heparin, was not affected by the administration 
of HTCC. Till now we have not studied the influence of HTCC on other blood components.  
The term ―chitosan‖ represents a large group of structurally different chemical entities obtained 
during the deacetylation of chitin under treatment with strong aqueous alkali. It is known that 
deacetylation degree is one of the most important features, which could influence biological activity  
of chitosan. Generally, the level of chitosan deacetylation is 70%–90% and it is thought that 70% 
deacetylation degree (DD 70%) is better and safer [5,15,30]. However, the higher acetylation, the 
lower solubility and higher possibility to induce an acute inflammatory response.  
On the other hand, it was reported that chitosans with acetylation degree higher than 35% show low 
toxicity [31]. In our study the acetylation of HTCC was found to be 21.1% from the elemental analysis 
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(DD 78.9%). Since it is known that the cationic modification increases also zeta potential (a measure 
of the magnitude of the electrical charge at the double layer) that could lead to increasing cellular 
toxicity, we decided to test safety of in vivo administration of HTCC using a rat model of acute 
toxicity. We found that chitosan samples are subjected to particularly rapid plasma clearance after i.v. 
injection with good distribution to all organs and high concentration in the liver [32]. 
Based on histopathological analysis, we have found the features of steatosis in response to i.p. 
administration of tested substance in a dose of 25 mg/kg. After i.p. administration of HTCC in 200  
and 500 mg/kg/day doses, we found some features of the liver damage (microvesicular fatty changes 
concentrated around central veins, the signs of severe congestion). These findings are consistent with 
those from other research which found hepato-nephrotoxicity induced by chitosan administration in 
mice [33]. Moreover, some studies regarding the interaction between human liver cells and chitosan 
nanoparticles in cell culture tests showed necrotic and autophagic cell death, possibly caused by the 
cell membrane damage by chitosan given at concentrations above 0.5% w/v [34]. It was also observed 
that oral 150 and 300 mg/kg doses of chitosan caused significant increase in the levels of liver 
enzymes in mice [33]. However, it was shown that chitosan may prevent liver injury. Some studies 
demonstrated that chitosan decreased plasma level of ALT and AST in the rat model of steatohepatitis 
or obesity and possesses the hepatoprotective activity [35–37]. It is well known that quaternized 
chitosans are non-cytotoxic and have many beneficial effects [10]. On the other hand, not all chitosan 
derivatives proved to be nontoxic—e.g., tertiary amines are less cytotoxic than primary ones as found 
by in study with Monomac cells [38]. 
The i.v. dose of HTCC used in rats to reverse heparin activity was 11.6 mg/kg. HTCC at the above 
dose is safe and, as revealed by the observation of the immediate normalization of APTT, it is a very 
strong heparin complexing agent. This phenomenon appears to be analogous to heparin complexation 
by protamine. Although chitosan has profound application in many fields of life, only several articles 
concern its harmful side effects. Unquestionably, chitosan could induce different dose-dependent 
organ damages [33,39]. Thus, special care should be taken especially when long term use of chitosan 
would be taken into account. 
During the last decade, several alternative methods were investigated for the reversal of  
heparin-induced anticoagulation. As an alternative to protamine administration a heparin removal 
device that uses extracorporeal circuit with plasma separation and poly-L-lysine affinity adsorption 
was proposed [40]. Methylene blue and vancomycin were also studied as heparin antidote. However, 
methylene blue produced incomplete reversal, and in comparison to protamine and vancomycin, it is 
toxic and ineffective. It seemed that for patients with protamine allergy hexadimethrine could be an 
alternative for heparin neutralization. However, some animal studies revealed its renal toxicity [41]. 
Some studies indicate that heparinase is highly effective in eliminating the anticoagulant activity of 
heparin in vitro in plasma from cardiac surgical patients [42]. On the other hand, heparinase used for 
heparin anticoagulation reversal in patient after aorto-coronary bypass graft surgery has inferior safety 
profile, compared to protamine [43]. In addition, platelet factor 4 is a very promising compound as a 
heparin-binding protein and was used safely in recombinant form in patients after cardiac 
catheterization [44]. Likewise, concatemeric heparin-binding peptides are potential candidates for the 
clinical reversal of heparin in humans [45]. In the above context it should finally be noted that HTCC 
may represent a completely novel class of heparin-neutralizing agents. 
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There are also some limitations to the present study that we want to underline strongly at  
the end of this discussion. We used APTT and PT as the end-point for heparin reversal and these are 
routinely measured standard parameters of blood coagulation [46,47]. However, there are data 
supporting also the application of anti-Xa, anti-IIa, and thrombin generation assays for anticoagulation 
measuring [13,48,49]. However, as yet there is no gold standard for the determination of complete 
heparin activity reversal, especially in animal studies [12,50]. The methods and reagents used in our 
study are particularly suitable for basal determination of functioning of extrinsic and intrinsic 
pathways of coagulation system. It seems important to test the participation of other elements of 
coagulation system, e.g., a function of blood platelets, red blood cells and vascular wall (endothelial 
function), in response to HTCC. Thus, further studies will certainly be needed. 
5. Conclusions 
In summary, HTCC is very effective in reversing heparin-induced anticoagulation both in vitro and 
in vivo in rats and its potency is comparable to that of protamine. As revealed by the anticoagulation 
measurements and histopathological results HTCC, when administered alone at doses adjusted for 
effective heparin complexation, is non-toxic and safe. This study for the first time shows the importance 
of cationically modified chitosans for potential development of a qualitatively new class of anti-heparins.  
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